AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01424397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP
Description: 200ug intranasal
Study NCT01424397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo intranasal
Study NCT04364139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP goal less than or equal to 92 mm Hg
Description: Lower Blood Pressure Goal (mean arterial pressure (MAP) less than or equal to 92 mm Hg) which corresponds to a BP of approximately 115/80 mmHg
Study NCT04364139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP goal 102-107 mm Hg
Description: Usual Blood Pressure Goal (mean arterial pressure (MAP) 102-107 mm Hg) which corresponds to a BP of approximately 135/85 to 140/90 mmHg
Study NCT04364139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: An angiotensin-converting enzyme inhibitor, (ACEI: ramipril) 2.5 to 10 mg/d
Study NCT04364139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: A dihydropyridine calcium channel blocker, (DHPCCB: amlodipine) 5 to 10 mg/d
Study NCT04364139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: A sustained release beta-blocker, (BB: metoprolol) 50 to 200 mg/d
Study NCT01294215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine (Adalat, BAYA1040)
Description: Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)
Study NCT01808339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate (FF)
Description: Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).
Study NCT01808339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
Study NCT01808339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
Study NCT04981158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: (Epidural /GA using tolerable endotracheal tube (TET) group, group II
Description: patients will undergo a single shot epidural bupivacaine (15 ml with 0.25% concentration) followed by a standard general anesthetic technique in which the trachea was intubated using TET, through its side port 2mg/kg , lidocaine 2% will be sprayed immediately after intubation when the patient is in flat supine position then the same dose of lidocaine will be repeated 10 minutes before anesthetic discontinuation.
Study NCT04981158 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: standard general anesthetic technique, control group, group I
Description: patients will undergo standard general anesthesia with classic endotracheal tube
Study NCT01933802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intrathecal administration of autologous MSC-NP
Description: Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
Study NCT00158782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.
Study NCT01340612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.
Description: Standard procedure for stenting. Addition of coils to the stent is left to the judgment of the treating physician
Study NCT03562533 — intervention group
Intervention type: DRUG
Intervention: pegylated liposomal doxorubicin (PLD) + carboplatin (CD)
Description: carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
Study NCT03562533 — intervention group
Intervention type: DRUG
Intervention: carboplatin + paclitaxel (CP)
Description: carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
Study NCT04345042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic Massage (Swedish Technique)
Description: Classic Massage (Swedish Technique); The massage was applied to the paitents with NP in the second group. Massage procedure included 3 strokes, 3 kneads, and 3 strokes to the upper back and neck area. The application was supported by face cradle and carried out in a semi-horizontal position in which the neck was relaxed. The patient was lying in supine position.
Study NCT00791570 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VEGFR1 and VEGFR2
Description: Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study NCT03187275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swedish Massage Therapy
Description: The therapist uses non-aromatic massage oil to facilitate making long, smooth strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then covered up before moving onto another part of the body. Primary techniques used in the research protocol therapy are: effleurage, petrissage, tapotement. These will be administered according to a very specific, standardized protocol. The total session time will be 45 minutes.
Study NCT03187275 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light Touch Intervention
Description: The light-touch research intervention is based on the concept that there will be a noticeable effect with regard to massage when compared to light-touch alone without the massage. The protocol followed will be the same as the massage protocol other than that the therapist will use light-touch only. The total session time will be 45 minutes.
Study NCT02814578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical coherent tomography
Description: comparative method for BVS
Study NCT02814578 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IntraVascular UltraSound
Description: The method of goldstandard for decision stent choice
Study NCT02197247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood sampling to measure AZD9291
Study NCT02197247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
Study NCT02197247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 tablet dosing
Description: Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
Study NCT02197247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - rifampicin
Description: Blood sampling to measure rifampicin levels
Study NCT02197247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples to measure levels of AZ5140 and AZ7550
Study NCT01934023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Champix (Varenicline) is an approved smoking cessation medication
Study NCT01934023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01267760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multipass hemodialysis
Description: 8-hour dialysis using a recycled dialysis bath of 25-30 l
Study NCT01676571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA21004
Description: 10 mg immediate-release (IR), one single dose, orally
Study NCT01060813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine supplements
Description: leucine supplements
Study NCT03478657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo DPI
Description: Subjects will receive placebo via oral inhalation route using ELLIPTA once daily. Placebo DPI will be available in two strips of 30 blisters per strip. First strip will contain lactose monohydrate and second strip will have lactose monohydrate blended with magnesium stearate.
Study NCT03478657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: Subjects will receive placebo DPI via ELLIPTA. ELLIPTA is trademark of GSK
Study NCT03478657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ease of use questionnaires
Description: Subjects from both stratum after use of ELLIPTA DPI will be randomized to receive either version A or B of the questionnaires. Subjects will be asked questions on ease of use of ELLIPTA. Parent/guardian will also complete a questionnaire about the ELLIPTA DPI.
Study NCT02983825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP); level changes
Description: as per arm description
Study NCT00415805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multihance
Description: 0.5 Molar, single injection at 0.2 mL/kg
Study NCT00415805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vasovist
Description: 0.25 molar single injection 0.03 ml/kg
Study NCT00169546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate
Study NCT00169546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Study NCT02479542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Gauze Dressing
Description: Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the control arm, only standard gauze dressings will be applied and changed daily. Wounds with the standard gauze dressings will be photo-documented and measured with the same variables every 72 hours. Wounds and dressing will be evaluated daily for drainage, exudate, presence of infection, and gauze dressings will be changed daily.
Study NCT02479542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WiCare NPWT dressing
Description: Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the simplified NPWT arm, the standard gauze dressing will be placed then the the WiCare NPWT dressing will be applied. Wounds and WiCare NPWT device will be evaluated daily for drainage, exudate, presence of infection, drainage in pump, integrity of air tight seal. Wounds will be changed by protocol with photo documentation every 72 hours for a total of 18 days or achievement of primary endpoint.
Study NCT00397345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trovax
Description: 1ml IM injection 2-8 weeks apart.
Study NCT00397345 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00397345 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care therapy
Description: subcutaneous low dose IL-2, interferon-α or sunitinib
Study NCT00397345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard of care therapy
Description: subcutaneous low dose IL-2, interferon-α or sunitinib
Study NCT01197261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone naloxone prolonged release tablets
Description: 2 tablets/ day
Study NCT01197261 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: 2 tablets/ day
Study NCT01781975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Study NCT01781975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (For imatinib mesylate)
Study NCT01940601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balugrastim
Description: Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
Study NCT01887782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFL rTMS
Description: Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
Study NCT01887782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS
Description: Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
Study NCT02585726 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SP-402 VenaSeal™ Closure System
Description: A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..
Study NCT02585726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SP-402 VenaSeal™ Closure System
Description: A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..
Study NCT01940601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Filgrastim 5 μg/kg
Study NCT02627521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRU guided CABG
Description: Coronary Artery Bypass Surgery
Study NCT02627521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG per standard of care
Description: Coronary Artery Bypass Surgery
Study NCT03737422 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hesperidin and flaxseed
Description: 2 capsuls hesperidin and 30 g flaxseed
Study NCT03737422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no supplementation
Study NCT01840228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micronized progesterone suppository
Study NCT01840228 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Micronized progesterone suppository
Study NCT01508494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: 16 mg galantamine daily P/O
Study NCT01508494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00997178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Description: Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse
Study NCT00997178 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Delayed non-surgical periodontal therapy
Description: Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
Study NCT03558451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex intervention in sexual health
Description: EXIMe is a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
Study NCT03558451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: According to available protocols applicable to the patient and the health service standardized portfolio
Study NCT03558451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: According to available protocols applicable to the patient and the health service standardized portfolio
Study NCT04217083 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breath sampling
Description: The alveolar fraction of Colorectal cancer patients and Healthy controls will be sampled using a breath sampler able to fix the volatile organic compound on absorbable tubes
Study NCT01428999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotics
Description: probiotics 1 pack (2g) bid for three weeks
Study NCT01428999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: probiotics 1 pack (2g) bid for three weeks
Study NCT04157647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb
Description: The hemadsorption filter will be included in the CPB circuit between the oxygenator and the venous reservoir. After cardiac surgery, the use of the filter will be continued till 24 hours after the end of surgery.
Study NCT04157647 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No hemadsorption filter or other treatment will be included in the CPB circuit
Study NCT01671956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bertilimumab
Description: IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
Study NCT01671956 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
Study NCT02999880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polychromatic layering
Description: Only two composite resin material shades will be used (opaque dentine composite and enamel shade composite).
Study NCT01305213 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study NCT01305213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01305213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosbretabulin Tromethamine
Description: Given IV
Study NCT01305213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01305213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01868776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buffered lidocaine
Study NCT01868776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nonbuffered lidocaine
Study NCT00729326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection (5mcg or 10mcg), twice a day
Study NCT00729326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: oral administration (100mg), once a day in the morning
Study NCT00729326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: subcutaneous injection (5mcg or 10mcg), twice a day
Study NCT00729326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral administration (100mg), once a day in the morning
Study NCT04468334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LARIAT + PVI
Description: LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures
Study NCT03247413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg/ml
Description: dexamethasone 4 milligram given post-ablation at each lesion site
Study NCT03247413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo, normal saline administered post-ablation at each lesion site
Study NCT01606735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090
Description: dexamethasone
Study NCT04503928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euphorbia kansui Pill
Description: 1 g (10 pills) of Euphorbia kansui Pill taken by mouth, once a day for 7 consecutive days.
Study NCT01762306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium
Study NCT01762306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Study NCT03008733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound UHF peripheral nerves
Description: Ultrasound UHF peripheral nerves
Study NCT03008733 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound UHF peripheral nerves
Description: Ultrasound UHF peripheral nerves
Study NCT03008733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electro myography surface nerves
Description: Electro myography surface nerves
Study NCT05333484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programed Pilates
Description: The 60 min Pilates sessions were held twice a week for 12 weeks. Each session included three stages: 10 min of warm-up exercises, 40 min of floor-based Pilates training, and 10 min of cool-down exercises. Each stage was adjusted according to the participants' physical capacity. Only participants with an attendance rate of > 80% were included in the final sample. The content of the exercise program was determined according to their muscular strength, flexibility, and fitness levels. The training course was divided into three levels: elementary, intermediate, and advanced. Each motion was performed in conjunction with a specific breathing pattern for effective muscle activations of each exercise.
Study NCT00888459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine replacement therapy
Description: 4 mg nicotine lozenges, ad lib, for 12 weeks.